Imatinib (Gleevec™)

Last Updated: 02/27/17

Status: Currently a NF2 Clinical Trial

Index

  • Trials
  • Other Known Uses
  • Side Effects
  • Special Precautions
Other Names Gleevec, Glivec, 152459-95-5, sti-571, Cgp 57148, STI 571, STI571, 1iep, 1xbb, Imatinib free base, Imatinib (INN)
Pharmaceutical Company Novartis
Treatment By Pill - Oral
Tumor Target Vestibular Schwannoma
Inhibitor Tyrosine Kinase Inhibitor
the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells
Molecular Formula C29H31N7O
IUPAC 4-[(4-Methyl-1-piperazinyl)methyl]-N-(4-methyl-3-{[4-(3-pyridinyl)-2-pyrimidinyl]amino}phenyl)benzamide
ChemSpider CSID:5101
PubChem CID 5291

Trials

  • Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas (0908-09) - www.ClinicalTrials.gov
  • Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec Indicated Hematological Disorders. - www.ClinicalTrials.gov

Other Known Uses

  • Chronic Myelogenous Leukemia (CML)
  • Gastrointestinal Stromal Tumors (GISTs)
  • Systemic Mastocytosis
  • Hypereosinophilic Syndrome
  • Dermatofibrosarcoma Protuberans
  • For treatment of Progressive Plexiform Neurofibromas associated with Neurofibromatosis Type I, early research has shown potential for using the c-kit tyrosine kinase blocking properties of Imatinib.

Special Precautions

  • Tell your doctor and pharmacist if you are allergic to imatinib or any other medications
  • Tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, and nutritional supplements you are taking or plan to take.
  • Tell your doctor what herbal products you are taking, especially St. John's wort.
  • Tell your doctor if you have or have ever had high blood pressure; a heart attack; an irregular heartbeat; diabetes; or heart, lung, thyroid, or liver disease. Also tell your doctor if you smoke, if you use street drugs, and if you drink or have ever drunk large amounts of alcohol.
  • Tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while you are taking Imatinib.
  • Tell your doctor if you are breast-feeding. You should not breast-feed while you are taking Imatinib.
  • Talk to your doctor about what you should do if you develop diarrhea during your treatment. Do not take any medications to treat diarrhea without talking to your doctor.

Side Effects

Minor

  • Anxiety
  • Constipation
  • Depression
  • Diarrhea
  • Gas
  • Indigestion
  • Joint Pain
  • Loss Of Appetite
  • Muscle Cramps
  • Nausea
  • Night Sweats
  • Teary Eyes
  • Vomiting

Serious - Contact doctor

Major side effects are uncommon. Since people with NF2 are taking these medications at a low dose, only minimal side effects are common. However, long term use is primarily where these major side effects take place. Monthly Blood and Urine Tests can usually point to an issue before it's a real problem. Talk to your doctor.

  • Blood In The Stool
  • Chest Pain
  • Coughing Up Pink Or Bloody Mucus
  • Difficulty Falling Asleep Or Staying Asleep
  • Dizziness
  • Excessive Tiredness Or Weakness
  • Fainting
  • Fast, Irregular, Or Pounding Heartbeat
  • Fever
  • Headache
  • Increased Urination, Especially At Night
  • Puffiness Under The Eyes
  • Rash Or Blisters
  • Shortness Of Breath
  • Sore Throat, Fever, Chills, And Other Signs Of Infection
  • Swelling Of The Hands, Feet, Ankles, Or Lower Legs
  • Unusual Bruising Or Bleeding
  • Weight Gain
  • Yellowing Of The Skin Or Eyes
What is NF2? | About Us | Treatment Options | Sitemap

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2008 - 2017